title: Ezetimibe in sirolimus-associated hyperlipidemia: to add or not to add to statins?
abstract: BACKGROUND
  Hyperlipidemia is a universal adverse effect of proliferation signal inhibitors (PSI). We report our experience with ezetimibe/statin combined therapy in a case of a kidney transplant recipient receiving sirolimus (SRL)-based immunosuppression. We also present our doubts concerning the need for ezetimibe in kidney transplant recipients on PSI-based immunosuppression.
  
  
  METHODS
  Results. In the reported patient, ezetimibe/statin combination therapy successfully decreased cholesterol level.
  
  
  CONCLUSIONS
  Combined therapy with ezetimibe and statin seems to be effective and safe in transplant recipients with SRL-associated hyperlipidemia. However, well-designed clinical trials should be performed to evaluate if there is an impact of such treatment on the frequency of cardiovascular events and patient survival.
authors.affiliation: Department of Immunology, Transplant Medicine and Internal Diseases, Medical University of Warsaw, Poland. mariuszniemczyk@wp.pl
authors.forename: Mariusz
authors.initials: M
authors.lastname: Niemczyk
authors.forename: Leszek
authors.initials: L
authors.lastname: Paczek
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D001384:Azetidines / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D020123:Sirolimus / Q000009:adverse effects*; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D008077:Lipoproteins, LDL; D014280:Triglycerides; D000069438:Ezetimibe; D020123:Sirolimus